#EMPEROR PRESERVED trial was recently published in #NEJM in 2021. It was also presented at #ESC2021. Heart Failure with Preserved Ejection Fraction (#HFpEF) is responsible of more than half of the cases of heart failure. It is a difficult to diagnose and difficult to treat condition. #Emplagliflozin and #dapagloflozin are 2 #SGLT2inhibitors have been found to be useful drugs in the management of #heart failure with reduced ejection fraction. The EMPEROR REDUCED and DAPA-HF trials have proven the efficacy of both these drugs in #heartfailure with reduced ejection (HFrEF). The #EMPEROR PRESERVED trial tested that whether #emplagliflozin can be useful in the management of Heart Failure with Preserved Ejection Fraction (#HFpEF).